сделать стартовой добавить в избранное карта сайта Remedium Group
Журнал Ремедиум
16 - 02 - 2019 [7:21]

об издании/about

новости/news

архив/archive

авторам/authors

подписка/subscription

книги Ремедиум/books

реклама в издании/advertising

контакты/contact


условия использования материалов



Авторизация на сайте
Логин:
Пароль:

Место для Вашей рекламы
Место для Вашей рекламы
Место для Вашей рекламы

Журнал "Ремедиум "в„–6 за 2018


Фармрынок / Pharmmarket

Рациональная фармакотерапия язвенного колита: метаанализ и клинико-экономические аспекты современных схем лекарственной терапии / Rational drug therapy of ulcerative colitis: meta-analysis and clinical and economic aspects of modern therapy regimens

DOI: http://dx.doi.org/10.21518/1561-5936-2018-6-34-42

Шаталова О.В.,  д.м.н., В.С. Горбатенко, к.м.н., Волгоградский государственный медицинский университет

Язвенный колит (ЯК) – хроническое идиопатическое рецидивирующее воспалительное заболевание толстого кишечника, приводящее к инвалидизации лиц трудоспособного возраста [1--3]. С ростом урбанизации и экономического развития, в промышленно развитых странах наблюдается быстрый рост заболеваемости ЯК.  По прогнозам, рост заболеваемости потребует реструктуризации оказания медицинской помощи с данной патологией [4].

O.V. Shatalova, MD, V.S. Gorbatenko, PhD in medicine Volgograd State Medical University 

Ulcerative colitis (UC) is an idiopathic chronic relapsing inflammatory disease of the large intestine, leading to disability of working-age people [1–3]. Due to the growth of urbanization and economic development, there is a rapid increase in the incidence of UC in the industrialized countries. According to the forecasts, the increase in morbidity will require the restructuring of medical care to the patients with this pathology [4]. 

Список литературы

1. H.ivik ML. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. H.ivik ML, Moum B, Solberg IC, et al. Gut 2013. 62. 368–75.

2. Torres J. Ulcerative colitis as a progressive disease: the forgotten evidence. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel J-F. Inflamm Bowel Dis 2012. 18. 1356–63.

3. Ungaro R. Ulcerative colitis. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Lancet. 2017. 389. 1756–1770 .

4. Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016. 1: 307–16.

5. Bonovas S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. S. Bonovas, T. Lytras,   G. Nikolopoulos, L. Peyrin-Biroulet, S. Danese Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 142. e42.

6. Ungaro R. Ulcerative colitis. Ungaro R, Mehandru S, Allen PB, et al. Lancet. 2017 .389. 1756–70.

7. Cohen RD, Systematic review: the costs of ulcerative colitis in Western countries. Cohen RD, Yu AP, Wu EQ, et al. Aliment Pharmacol Ther. 2010. 31693–707.2

8. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013. 2. 42-46.

9. Dignass A. et al. Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management, Journal of Crohn's and Colitis. 2012.

10.Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011. 106: 685-698.

11.Ford AC, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Ford AC, Sandborn WJ, Khan KJ, et al. Gastroenterology. 2011. 106. 644–659.

12.Feagan BG, Vedolizumab as induction and maintenance therapy for ulcerative colitis. Feagan BG, Rutgeerts P, Sands BE, et al. N Engl J Med. 2013. 369.   699–710.

13.Reinisch W, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Reinisch W, Sandborn WJ, Hommes DW, et al. Gut. 2011. 60. 780–787.

14. Sandborn WJ, Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Sandborn WJ, Feagan BG, Marano C, et al. Gastroenterology. 2014. 146. 85-95.

15. Sandborn WJ, Tofacitinib as induction and maintenance therapy for ulcerative colitis. Sandborn WJ, Su C, Sands BE, et al.   NEngl JMed. 2017. 376. 1723–1736.

16. Ben-Horin S. Optimizing anti-TNF treatments in inflammatory bowel disease. S.Ben-Horin, U.Kopylov, Y.Chowers. Autoimmun Rev. 2013. 13. 24–30

17. Головенко А.О. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. А.О. Головенко, И.Л. Халиф, О.В. Головенко и др. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013. 23. 5. 65-73.

18. Lee K.M. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. K/M/Lee, Y.T.Jeen, J.Y.Cho et al. J Gastroenterol Hepatol. 2013. 28. 1829–1833.

19. Taxonera C. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. M.Barreiro-de Acosta, M.Calvo et al. Dig Dis Sci. 2015. 60. 3075–3084.

20. Wolf D. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. D.Wolf, G.D'Haens, W.J.Sandborn et al. Aliment Pharmacol Ther. 2014. 40. 486-497.

21. Sandborn, W.J. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: Clinical efficacy and pharmacoeconomics. W.J. Sandborn, J.F. Colombel, S. Schreiber et al. Inflamm Bowel Dis. 2011. 17. 141–151.

22. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2 и OCTAVE Sustain Investigators. N Engl J Med. 2017. 4, 376 (18): 1723-1736.

23. Cipriani A, Conceptual and technical challenges in network meta-analysis. Cipriani A, Higgins JP, Geddes JR, et al. Ann Intern Med. 2013. 159. 130–137.

24. Cite this article: FDA Panel Backs Proposed Tofacitinib Dosing for Ulcerative Colitis – Medscape – Mar 09, 2018.

25. Rutgeerts P, Infliximab for induction and maintenance therapy for ulcerative colitis. Rutgeerts P, Sandborn WJ, Feagan BG, et al. N Engl J Med. 2005. 353. 2462–2476.

26. Jiang XL, Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis. Jiang XL, Cui HF, Gao J, et al. J Clin Gastroenterol. 2015. 49. 582–588.

27. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Reinisch W, Sandborn WJ, Hommes DW, et al. Gut. 2011. 60. 780–787.

28. Sandborn WJ, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Sandborn WJ, van Assche G, Reinisch W, et al. Gastroenterology. 2012,142. 257–265.

29. Suzuki Y, Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Suzuki Y, Motoya S, Hanai H, et al. Gastroenterology. 2014. 49. 283–294 .

30. Sandborn W.J. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate to Severe Ulcerative Colitis. W.J.Sandborn, B.G.Feagan, C.Marano et al. Gastroenterology. 2013. 146. 85-95.

31. Sandborn W.J. Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-To-Severe Ulcerative Colitis. W.J. Sandborn, B.G. Feagan, C. Marano et al. Gastroenterology. 2013. 146. 96-109.

32. Hibi T, Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). Hibi T, Imai Y, Senoo A, et al. Gastroenterology. 2017.

33. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013. 369: 699-710.

34. SandbornWJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017. 376: 1723-1736.

Ключевые слова: язвенный колит, метаанализ, клинико-экономический анализ, фармакоэкономический анализ, эффективность затрат, минимизация затрат, генно-инженерная биологическая терапия, ГИБП, ингибитор ФНО-α, ингибитор Янус-киназ, адалимумаб, цертолизумаба пэгол

Статья Аrticle Загрузить
Размер файла: 2520 кбайт
Формат: Pdf


Вернуться назад

Архив номеров
Archive of "Remedium"

2018.jpg
2017.jpg
2016.jpg
2015.jpg
2014.jpg
2013.jpg
2012.jpg
2011.jpg
2010.jpg
2009.jpg
2008.jpg
2007.jpg
2006.jpg
2005.jpg
2004.jpg
2003.jpg
2002.jpg


Издание зарегистрировано в Комитете по печати РФ
Рег. свидетельство ПИ №77-1138,
выдано 25.11.1999
об издании/about реклама/advertising подписка/subscription архив/archive контакты/contactусловия использования материалов
Яндекс цитирования
Rambler's Top100
Rambler's Top100

© Remedium 2014-2019
Все права защищены